ProQR Therapeutics Creating RNA therapies for patients in need

ProQR scientist working in the lab

Our science

Latest press releases

Internal link More press releases
Female scientist working in the lab

ProQR Community News

  • ProQR Update August 2022

    Community news

    Announced today (August 11, 2022), ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).

    RNA illustration

  • Building an Inclusive ProQR

    Community news

    At ProQR we strive to create an inclusive culture where everyone is valued for who they are and individual differences and contributions are recognized and appreciated. Therefore, we decided for this Pride Month June 2022, to visually demonstrate our support and acknowledgment of the LGBTQ+ community by changing our logo to incorporate the pride rainbow flag.

    Rainbow image with text We Wish You A Happy Pride Month!

Lilly partnership announcement

We announced a global licensing and research collaboration with Eli Lilly and Company focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s proprietary Axiomer® RNA editing platform to progress new drug targets toward clinical development and commercialization.

Internal link Read more
An illustration of an ADAR enzyme (in white) attached to an RNA molecule (in green)